BioStem Q2 2026 Net Loss $8.97M; Liquidity Concerns Raised

BioStem Technologies reported a significant net loss of $8.97 million for Q2 2026, a sharp decline from a net income of $10,613 in the prior year. For the six months ended June 30, 2026, the company incurred a net loss of $17.79 million, reversing a net income of $3.92 million from the same period in 2025. Revenue also decreased significantly. The company completed the acquisition of BioTissue's surgical and wound care business in January 2026, which contributed $6.71 million in Q2 revenue. However, BioStem raised substantial doubt about its ability to continue as a going concern due to expected net losses, negative cash flows, and obligations related to the acquisition and a restructured loan.